J. Senapati

发表

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

E. Jabbour, N. Short, H. Kantarjian, 2022, Leukemia.

Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation

P. Ray, P. Malhotra, M. Aggarwal, 2021, Therapeutic advances in infectious disease.

Antibody-Drug Conjugates in Myeloid Leukemias.

N. Daver, N. Pemmaraju, Jayastu Senapati, 2022, Cancer journal.

Which FLT3 Inhibitor for Treatment of AML?

T. Kadia, Jayastu Senapati, J. Senapati, 2022, Current Treatment Options in Oncology.

Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia

N. Jain, Jayastu Senapati, J. Senapati, 2021 .

Management of chronic myeloid leukemia in 2023 – common ground and common sense

J. Radich, H. Kantarjian, J. Lipton, 2023, Blood cancer journal.

Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects

K. Sasaki, Jayastu Senapati, J. Senapati, 2022, Cancers.

Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.

C. Mullighan, K. Patel, T. Kadia, 2023, JCO precision oncology.

Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma—A Single Center Experience

B. George, K. Lakshmi, V. Mathews, 2021, Indian Journal of Hematology and Blood Transfusion.

Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature

A. Viswabandya, A. Ganapule, Jayastu Senapati, 2014, Mediterranean journal of hematology and infectious diseases.

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Naveen Garg, Catherine J. Wu, P. Sharma, 2022, Blood advances.

Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country

T. Seth, M. Aggarwal, M. Mahapatra, 2021, Leukemia & lymphoma.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

Tele-Medicine Services in Hematological Practice During Covid Pandemic: Its Feasibility and Difficulties

Sri Krishna, T. Seth, Pradeep Kumar, 2020, Indian Journal of Hematology and Blood Transfusion.

Diffuse Large B Cell Lymphoma in Wiskott-Aldrich Syndrome: A Case Report and Review of Literature

B. George, G. Jayandharan, S. David, 2014, Indian Journal of Hematology and Blood Transfusion.

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations

G. Garcia-Manero, G. Borthakur, C. Dinardo, 2023, Leukemia.

Asymptomatic gastrosplenic fistula in a patient with marginal zonal lymphoma transformed to diffuse large B cell lymphoma—a case report and review of literature

A. Viswabandya, Jayastu Senapati, A. Devasia, 2014, Annals of Hematology.

Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens

T. Kadia, F. Ravandi, G. Borthakur, 2022, American journal of hematology.

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

G. Garcia-Manero, K. Patel, T. Kadia, 2020, American journal of hematology.

CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.

J. Khoury, N. Pemmaraju, N. Jain, 2022, Leukemia research.

A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies

H. Kantarjian, T. Kadia, E. Jabbour, 2022, Cancer.

Early T cell precursor lymphoid blast crisis of chronic myeloid leukemia - a novel transformation.

B. George, A. A. Alex, Jayastu Senapati, 2015, Hematology/oncology and stem cell therapy.

SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia

N. Short, M. Welch, F. Haddad, 2024, Clinical Lymphoma Myeloma and Leukemia.

Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B‐cell acute lymphoblastic leukemia

C. Mullighan, T. Kadia, F. Ravandi, 2023, American journal of hematology.

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study

M. Davids, K. Rogers, A. Kittai, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

M. Davids, C. Jacobson, N. Jain, 2023, Blood.

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.

K. Bhalla, G. Garcia-Manero, T. Kadia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.